Get all premium features to the best stock analysis tool

Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology

Kennewick, WA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company developing Precision Radionuclide Therapy™ (PRnT) for cancerous tumors in humans and animals, today announced the peer-reviewed publication of a paper describing the PrecisionGel™ thermogel polymer platform in the Journal of Drug Delivery Science and Technology.

Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center

Kennewick, WA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, today announced two significant operational milestones: the commencement of IsoPet® shipments from its new in-house U.S. production facility, and the receipt of authorization from The Atomic Energy Regulatory Board (AERB) of India, India's national nuclear safety regulator, equivalent to the U.S. Nuclear Regulatory Commission, to proceed with an international manufacturing center in India. Together, these milestones establish Vivos as a dual-site global production organization for the first time in the Company's history.